Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIP4K2A | P48426 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 5/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | FADS1 | O60427 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3794278 | 0.99 | PIP4K2A (0.48) | PIP4K2AMEN1KMT2ARAB9AEGFR | |
| SCHEMBL3794281 | 0.80 | MEN1 (0.52) | PIP4K2AMEN1KMT2ARAB9AEGFR | |
| SCHEMBL3796906 | 0.80 | IRAK4 (0.52) | PIP4K2AMEN1KMT2ARAB9AEGFR | |
| SCHEMBL3802228 | 0.79 | IRAK4 (0.53) | PIP4K2AMEN1KMT2ARAB9AEGFR | |
| SCHEMBL3801794 | 0.77 | MEN1 (0.53) | PIP4K2AMEN1KMT2ARAB9AEGFR | |
| SCHEMBL3797986 | 0.76 | MEN1 (0.54) | PIP4K2AMEN1KMT2ARAB9AEGFR | |
| SCHEMBL3801664 | 0.74 | RAB9A (0.50) | PIP4K2AMEN1KMT2ARAB9AEGFR | |
| SCHEMBL3797489 | 0.73 | RAB9A (0.50) | PIP4K2AMEN1KMT2ARAB9AEGFR | |
| SCHEMBL3799139 | 0.72 | MEN1 (0.54) | PIP4K2AMEN1KMT2ARAB9AEGFR | |
| SCHEMBL9431935 | 0.72 | KMT2A (0.54) | PIP4K2AMEN1KMT2ARAB9AEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100143341-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2010-06-10 | — | — | US | claimed |
| EP-1899353-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DeveloGen Aktiengesellschaft (DE) | 2008-03-19 | — | — | EP | claimed |
| WO-2007059905-A9 | THIENOPYRIMIDINES TREATING INFLAMMATORY DISEASES | DEVELOGEN AG (DE) | 2007-11-01 | — | — | WO | claimed |
| WO-2007059905-A2 | THIENOPYRIMIDINES TREATING INFLAMMATORY DISEASES | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2007-05-31 | — | — | WO | claimed |
| WO-2006136402-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2006-12-28 | — | — | WO | claimed |
| US-20100143341-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2010-06-10 | — | — | US | disclosed |
| EP-1899353-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DeveloGen Aktiengesellschaft (DE) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007059905-A9 | THIENOPYRIMIDINES TREATING INFLAMMATORY DISEASES | DEVELOGEN AG (DE) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007059905-A2 | THIENOPYRIMIDINES TREATING INFLAMMATORY DISEASES | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2007-05-31 | — | — | WO | disclosed |
| WO-2006136402-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100143341-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DTYMK, CMPK1, PDXK | PIP4K2A 84/4885MEN1 1106/4885KMT2A 1016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.